SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Emisphare teaming up with Novartis and Roch
An SI Board Since November 2004
Posts SubjectMarks Bans
4 1 0
Emcee:  Alfred W. Post Type:  Unmoderated
In September, Emisphere announced that it entered into a licensing agreement with Novartis Pharma AG to develop an oral formulation of recombinant human growth hormone (rhGH). Under the terms of the milestone- based agreement, Novartis may pay Emisphere up to $34 million during the course of product development, and a royalty increasing to double-digit rates based upon sales. Including the initial payment, Emisphere could achieve milestone-based payments of up to $6 million over the course of the next year.

The companies formed the agreement following successful completion of pre-clinical feasibility studies for rhGH with Emisphere's eligen(R) technology. Emisphere identified delivery agents that can deliver therapeutically sufficient levels of rhGH to the blood stream when administered orally. The lead carrier for rhGH has completed extensive formulation and preclinical safety studies.

A similar collaboration has been nade between Emisphere and Roch.
Making it possilbe to switch from injecting meicine to absorging it through pills orally would be a great accivment.
 Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
 Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):